Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. (MBIO)
Last mustang bio, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
mustangbio.com/investor-relations
Company Research
Source: GlobeNewswire
WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the first patient successfully received LV-RAG1 ex vivo lentiviral gene therapy to treat recombinase-activating gene-1 (“RAG1”) severe combined immunodeficiency (“RAG1-SCID”), in an ongoing Phase 1/2 multicenter clinical trial taking place in Europe. LV-RAG1 is exclusively licensed by Mustang for the development of MB-110, a first-in-class ex vivo lentiviral gene therapy for the treatment of RAG1-SCID. Patients with SCID have mutations in blood stem cell genes that are responsible for the development and function of infection-fighting immune cells. As a result, they are unable to mount a normal defense response against infections. The administration of LV-RAG1
Show less
Read more
Impact Snapshot
Event Time:
MBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBIO alerts
High impacting Mustang Bio, Inc. news events
Weekly update
A roundup of the hottest topics
MBIO
News
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesGlobeNewswire
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma [Yahoo! Finance]Yahoo! Finance
MBIO
Earnings
- 11/14/23 - Beat
MBIO
Sec Filings
- 3/15/24 - Form S-1
- 3/15/24 - Form 8-K
- 3/11/24 - Form 8-K
- MBIO's page on the SEC website